JP2020519627A - 神経保護および再ミエリン化のための可溶性ｃｄ２４の使用方法 - Google Patents

神経保護および再ミエリン化のための可溶性ｃｄ２４の使用方法 Download PDF

Info

Publication number
JP2020519627A
JP2020519627A JP2019562255A JP2019562255A JP2020519627A JP 2020519627 A JP2020519627 A JP 2020519627A JP 2019562255 A JP2019562255 A JP 2019562255A JP 2019562255 A JP2019562255 A JP 2019562255A JP 2020519627 A JP2020519627 A JP 2020519627A
Authority
JP
Japan
Prior art keywords
protein
hours
use according
cd24fc
minutes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019562255A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020519627A5 (https=
Inventor
リウ，　ヤン
ヤン リウ，
パン ジェン，
パン ジェン，
ニン リー，
ニン リー，
マーティン デベンポート，
マーティン デベンポート，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Childrens National Medical Center Inc
Original Assignee
Childrens National Medical Center Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Childrens National Medical Center Inc filed Critical Childrens National Medical Center Inc
Publication of JP2020519627A publication Critical patent/JP2020519627A/ja
Publication of JP2020519627A5 publication Critical patent/JP2020519627A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/528—CH4 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
JP2019562255A 2017-05-15 2018-05-15 神経保護および再ミエリン化のための可溶性ｃｄ２４の使用方法 Pending JP2020519627A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762506135P 2017-05-15 2017-05-15
US62/506,135 2017-05-15
PCT/US2018/032699 WO2018213266A1 (en) 2017-05-15 2018-05-15 Methods of use of soluble cd24 for neuroprotection and remyelination

Publications (2)

Publication Number Publication Date
JP2020519627A true JP2020519627A (ja) 2020-07-02
JP2020519627A5 JP2020519627A5 (https=) 2021-05-06

Family

ID=64274583

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019562255A Pending JP2020519627A (ja) 2017-05-15 2018-05-15 神経保護および再ミエリン化のための可溶性ｃｄ２４の使用方法

Country Status (8)

Country Link
US (2) US20200181235A1 (https=)
EP (1) EP3624838B1 (https=)
JP (1) JP2020519627A (https=)
KR (1) KR20200034957A (https=)
CN (1) CN110650749A (https=)
CA (1) CA3063894A1 (https=)
TW (1) TW201900671A (https=)
WO (1) WO2018213266A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130231464A1 (en) 2010-04-28 2013-09-05 Oncolmmune, Inc. Methods of use of soluble cd24 for therapy of rheumatoid arthritis
WO2020084034A1 (en) 2018-10-26 2020-04-30 F. Hoffmann-La Roche Ag Multispecific antibody screening method using recombinase mediated cassette exchange
WO2021160170A1 (en) * 2020-02-10 2021-08-19 Oncoimmune, Inc. Methods of use of soluble cd24 for treating sars-cov-2 infection

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004500110A (ja) * 2000-03-29 2004-01-08 ジ・オハイオ・ステイト・ユニバーシティ・リサーチ・ファウンデイション 自己反応性ｔ細胞による組織破壊をブロックする方法
JP2013527168A (ja) * 2010-04-28 2013-06-27 オンコイミューン， インコーポレイテッド 関節リウマチの治療のための可溶性ｃｄ２４の使用方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7067110B1 (en) * 1999-07-21 2006-06-27 Emd Lexigen Research Center Corp. Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens
US20030106084A1 (en) * 2000-03-29 2003-06-05 Yang Liu Methods of blocking tissue destruction by autoreactive T cells
US20130231464A1 (en) * 2010-04-28 2013-09-05 Oncolmmune, Inc. Methods of use of soluble cd24 for therapy of rheumatoid arthritis
US10689447B2 (en) * 2011-02-04 2020-06-23 Genentech, Inc. Fc variants and methods for their production
CA2887682A1 (en) * 2012-10-09 2014-04-17 Biogen Idec Ma Inc. Combination therapies and uses for treatment of demyelinating disorders

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004500110A (ja) * 2000-03-29 2004-01-08 ジ・オハイオ・ステイト・ユニバーシティ・リサーチ・ファウンデイション 自己反応性ｔ細胞による組織破壊をブロックする方法
JP2013527168A (ja) * 2010-04-28 2013-06-27 オンコイミューン， インコーポレイテッド 関節リウマチの治療のための可溶性ｃｄ２４の使用方法

Also Published As

Publication number Publication date
TW201900671A (zh) 2019-01-01
EP3624838A4 (en) 2021-02-24
US20220098278A1 (en) 2022-03-31
KR20200034957A (ko) 2020-04-01
CA3063894A1 (en) 2018-11-22
CN110650749A (zh) 2020-01-03
WO2018213266A1 (en) 2018-11-22
US20200181235A1 (en) 2020-06-11
EP3624838A1 (en) 2020-03-25
EP3624838B1 (en) 2023-01-25

Similar Documents

Publication Publication Date Title
ES2341842T3 (es) Bloqueo del crecimiento axonal mediado por el receptor de nogo.
JP6364352B2 (ja) 部分的ｍｈｃコンストラクト及びその使用方法
JP6751756B2 (ja) 低密度リポタンパク質コレステロールレベルを低下させるためのｃｄ２４の使用
EP2313432B1 (en) Use of cd31 peptides in the treatment of thrombotic and autoimmune disorders
US20220098278A1 (en) Methods of Use of Soluble CD24 for Neuroprotection and Remyelination
US20130011835A1 (en) Compositions and methods for treating inflammation
US10034915B2 (en) Small heat shock proteins and active fragments thereof as a therapy for inflammation and ischemia
EP2332408A1 (en) Treating neurological disorders
US10316075B2 (en) Recombinant polypeptides comprising MHC class II α1 domains
WO2008053049A1 (en) Modulators of cell adhesion molecules and use thereof
JP7419229B2 (ja) 方法
KR20190126801A (ko) 전신 홍반성 루푸스를 치료하기 위한 가용성 cd24의 사용 방법
EP1476179A2 (en) Methods of preventing or treating brain ischemia or brain injury
WO2021262564A1 (en) Use of semaphorin-4d binding molecules for the treatment of rett syndrome
US20220000974A1 (en) Targeting CD24-Siglec Interactions for Treating Subjects with Prediabetes or Diabetes

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210323

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210323

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20210727

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20210803

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20210728

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220315

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20221011